Merck & Co., Inc. (NYSE:MRK), one of the largest pharmaceutical companies in the world, has lost 15% year-to-date on the ...

Neither the mid-stage nor the late-stage trial of Adagene’s drug needs an arm studying the drug as a monotherapy without Merck’s Keytruda, the company said.

Merck is tackling its looming “Keytruda cliff” with a bold $10 billion acquisition of Verona Pharma. The deal brings Ohtuvayre, a first-in-class COPD drug, into Merck’s portfolio as it looks to ...